Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Memantine: Phase III data; marketed in EU to treat Alzheimer’s disease (AD)

In a Phase III trial in diabetic patients, Memantine failed to

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE